BioSight
Companies
Tarsus Pharmaceuticals, Inc. logo

TARS

NASDAQIRVINE, CA
Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals is a commercial-stage ophthalmology company that has approved and is commercializing XDEMVY (lotilaner ophthalmic solution) 0.25%, a small molecule treatment for Demodex blepharitis. The company is also developing product candidates in additional ophthalmic indications including ocular rosacea, as well as pursuing development in non-ophthalmic areas such as Lyme disease and malaria.

Price history not yet available for TARS.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar